Inflammation across the spectrum of hypertrophic cardiac phenotypes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The hypertrophic cardiomyopathy phenotype encompasses a heterogeneous spectrum of genetic and acquired diseases characterized by the presence of left ventricular hypertrophy in the absence of abnormal cardiac loading conditions. This “umbrella diagnosis” includes the “classic” hypertrophic cardiomyopathy (HCM), due to sarcomere protein gene mutations, and its phenocopies caused by intra‐ or extracellular deposits, such as Fabry disease (FD) and cardiac amyloidosis (CA). All these conditions share a wide phenotypic variability which results from the combination of genetic and environmental factors and whose pathogenic mediators are poorly understood so far. Accumulating evidence suggests that inflammation plays a critical role in a broad spectrum of cardiovascular conditions, including cardiomyopathies. Indeed, inflammation can trigger molecular pathways which contribute to cardiomyocyte hypertrophy and dysfunction, extracellular matrix accumulation, and microvascular dysfunction. Growing evidence suggests that systemic inflammation is a possible key pathophysiologic process potentially involved in the pathogenesis of cardiac disease progression, influencing the severity of the phenotype and clinical outcome, including heart failure. In this review, we summarize current knowledge regarding the prevalence, clinical significance, and potential therapeutic implications of inflammation in HCM and two of its most important phenocopies, FD and CA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory profiling of patients with familial amyloid polyneuropathy
Azevedo, E. P., Guimaraes-Costa, A. B., Bandeira-Melo, C., Chimelli, L., Waddington-Cruz, M., Saraiva, E. M., Palhano, F. L., & Foguel, D. (2019) · BMC Neurology · doi:10.1186/s12883-019-1369-4 · Cited by 66 · cited 4×
“[75] found that asymptomatic patients with familial amyloid polyneuropathy (FAP) present high levels of IL-33, IL-1β, and IL-10, suggesting that inflammation has a role in the early stages of the disease.”
BackgroundResultInfluential
Cited by
Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Acute Myocarditis
Monda, E., Bakalakos, A., Cannie, D., O’Mahony, C., Syrris, P., Kaski, J. P., Limongelli, G., & Elliott, P. M. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2024.02.012 · Cited by 86
Peretto, G., Villatore, A., & Cooper, L. T. (2026) · Immunological Reviews · doi:10.1111/imr.70105 · Cited by 10
“Patients with end-stage HCM, where systolic function finally declines after years of hypertrophy, often show elevated circulating inflammatory cytokines, such as IL-6 and TNF-α, as well as the presence of neutrophil extracellular traps (NETs) [153, 156].”
Tao, W., Gong, M., & Ke, Z. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70554 · Cited by 4
Saha, D., Dutta, P., & Chakraborty, A. (2025) · Immuno · doi:10.3390/immuno5040045 · Cited by 3
Mahmoud, A. K., Awad, K., Sheashaa, H., Kandil, O., Farina, J. M., Ibrahim, R., Abdelnabi, M., Allam, M., Mital, R., Shipman, J., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag051 · Cited by 3
Metadata
- Authors
- Lillo, R., Graziani, F., Franceschi, F., Iannaccone, G., Massetti, M., Olivotto, I., Crea, F., & Liuzzo, G.
- Venue
- Heart Failure Reviews
- Published
- 2023-04-28
- Volume
- 28
- Issue
- 5
- Pages
- 1065-1075
- ISSN
- 1382-4147 (ISSN-L)
- 1573-7322
- OpenAlex
- W4367299966
- Cited by
- 62
- References
- 1
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation across the spectrum of hypertrophic cardiac phenotypes. https://app.cochat.ai/papers/10.1007/s10741-023-10307-4
- The paper
- Lillo, R., Graziani, F., Franceschi, F., Iannaccone, G., Massetti, M., Olivotto, I., Crea, F., & Liuzzo, G. (2023). Inflammation across the spectrum of hypertrophic cardiac phenotypes. Heart Failure Reviews. https://doi.org/10.1007/s10741-023-10307-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.